/Regeneron%20Pharmaceuticals%2C%20Inc_%20logo%20on%20phone-by%20Piotr%20Swat%20via%20Shutterstock.jpg)
Tarrytown, New York-based Regeneron Pharmaceuticals, Inc. (REGN) discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases. Valued at $73.8 billion by market cap, the company's portfolio boasts nine marketed drugs - Eylea, Dupixent, Praluent, Kevzara, Libtayo, Evkeeza, Inmazeb Arcalyst and Zaltrap.
Companies worth $10 billion or more are generally described as “large-cap stocks,” and REGN perfectly fits that description, with its market cap exceeding this mark, underscoring its size, influence, and dominance within the biotechnology industry. REGN has a strong product portfolio with marketed products like Eylea and Dupixent. The company's innovative pipeline and successful commercialization of products drive its financial performance. Strategic collaborations with Sanofi and Bayer enhance research capabilities. Regeneron's VelocImmune technology keeps it at the forefront of biotech innovation, generating revenue through shared profits and royalties.